|
|
Post by peppy on Aug 2, 2018 20:54:00 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 20:58:03 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 21:08:37 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 21:43:43 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 22:06:56 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 22:25:43 GMT -5
|
|
|
|
Post by peppy on Aug 2, 2018 22:32:00 GMT -5
net value per script 590 dollars.
|
|
|
|
Post by uvula on Aug 2, 2018 23:16:18 GMT -5
Does anyone understand the afrezza writers exceed 4.5% slide?
|
|
|
|
Post by peppy on Aug 2, 2018 23:37:52 GMT -5
Does anyone understand the afrezza writers exceed 4.5% slide? this is what I found, Pat McCauley So we like that we're ending on a high note, we're continuing to move forward with that. If you switch over now, let's take a closer look at the writer, same format, and what you see here are unique Afrezza writers per quarter, and that's just a simple way of saying that they prescribed at least one Afrezza prescription in a given quarter. Now as you can see in the second quarter of '18 in the top line, our Afrezza NRx market share exceeded 4.5%. You can also see that TRx has increased each quarter since the launch of the MannKind sales team. And we think this is really important, because it demonstrates that once a physician has made that clinical decision to prescribe Afrezza, we have a great opportunity to increase breadth and depth of prescribing. And when it comes to MannKind cares and patient referrals, I'm really excited to share with you that referrals have increased 73% from the first quarter of '18 to the second quarter of '18. |
|
|
|
Post by peppy on Aug 2, 2018 23:40:16 GMT -5
Mike C
I personally wanted to say I talked to a lot of the top payers within U.S. We continue to watch the government and what's happening within Medicare, around rebates being protected. And if that continues to change that only benefit us and clear the ways for prior authorizations and continue to remove restrictions around, I'll say, competitive-driven restrictions around Afrezza. And as that happens, we continue to see accelerated growth as doctors don't have to continue to do prior auth. But in the meantime, we've built the models, we continue to have great patient support, and we're seeing patients get approved seven to eight out of 10 times when they come through the prior auth process. So we feel good about where we are, and would continue to drive that demand.
peppy, it has been insurance this whole time. "I'll say, competitive-driven restrictions around Afrezza."
UnitedHealth Group Reports First Quarter Results
First Quarter Revenues of $55.2 Billion Grew 13.3% Year-Over-Year
Earnings from Operations Increased 18.8% to $4.1 Billion, with Every Business Reporting Double-Digit Percentage Earnings Growth
Cash Flows from Operations were $8.4 Billion in First Quarter; Adjusted Cash Flows from Operations were $3.2 Billion
First Quarter Net Earnings of $2.87 Per Share Grew 28.7% Year-Over-Year
First Quarter Adjusted Net Earnings of $3.04 Per Share Grew 28.3% Year-Over-Year
|
|
|
|
Post by peppy on Aug 3, 2018 0:00:08 GMT -5
I had a lot of question on the Tanner Pharma, I just wanted to address there is no upfront money because we still own global rights to Afrezza. Tanner Pharma is mainly meant to help patients, we get called every single week of people wanting Afrezza around the world, and we didn't have a mechanism to enable them to get it, whether it's through the government or through them purchasing it in cash -- in conjunction with their doctor. And Tanner Pharma has a name patient access program that enables people around the world to get Afrezza while we pursue regulatory approvals ourselves or continue to find a global partner to get the product ready registers, especially as we go to Europe and Australia. So that's why I had to explain that, so people weren't confused.
|
|
|
|
Post by uvula on Aug 3, 2018 0:01:08 GMT -5
Does anyone understand the afrezza writers exceed 4.5% slide? this is what I found, Pat McCauley So we like that we're ending on a high note, we're continuing to move forward with that. If you switch over now, let's take a closer look at the writer, same format, and what you see here are unique Afrezza writers per quarter, and that's just a simple way of saying that they prescribed at least one Afrezza prescription in a given quarter. Now as you can see in the second quarter of '18 in the top line, our Afrezza NRx market share exceeded 4.5%. You can also see that TRx has increased each quarter since the launch of the MannKind sales team. And we think this is really important, because it demonstrates that once a physician has made that clinical decision to prescribe Afrezza, we have a great opportunity to increase breadth and depth of prescribing. And when it comes to MannKind cares and patient referrals, I'm really excited to share with you that referrals have increased 73% from the first quarter of '18 to the second quarter of '18. Still don't understand. 4.5% of what? Is he saying that for doctors who prescribe afrezza, 4.5% of the rxs they write are for Afrezza? |
|
|
|
Post by peppy on Aug 3, 2018 0:14:47 GMT -5
this is what I found, Pat McCauley So we like that we're ending on a high note, we're continuing to move forward with that. If you switch over now, let's take a closer look at the writer, same format, and what you see here are unique Afrezza writers per quarter, and that's just a simple way of saying that they prescribed at least one Afrezza prescription in a given quarter. Now as you can see in the second quarter of '18 in the top line, our Afrezza NRx market share exceeded 4.5%. You can also see that TRx has increased each quarter since the launch of the MannKind sales team. And we think this is really important, because it demonstrates that once a physician has made that clinical decision to prescribe Afrezza, we have a great opportunity to increase breadth and depth of prescribing. And when it comes to MannKind cares and patient referrals, I'm really excited to share with you that referrals have increased 73% from the first quarter of '18 to the second quarter of '18. Still don't understand. 4.5% of what? Is he saying that for doctors who prescribe afrezza, 4.5% of the rxs they write are for Afrezza? writers........... HCP's with 1+ script written this quarter. on bottom of page. prescriber data from symphony.  ' |
|
|
|
Post by buyitonsale on Aug 3, 2018 0:47:19 GMT -5
I think 4.5% NRx market share = market share of all NRx
written for mealtime insulin
|
|
|
|
Post by peppy on Aug 3, 2018 3:02:13 GMT -5
I think 4.5% NRx market share = market share of all NRx written for mealtime insulin Afrezza----495 $632k 277 $380k Apidra----6520 $4.95m 2254 $1.77m Novalog--137k $132m 56.0k $57.8m Humalog-151k $139m 60.3k $58.0m Humalin--37.4k $20.5m 14.9k $8.0m |
|
